Literature DB >> 18465373

Anterior cingulate glutamate-glutamine levels predict symptom severity in women with obsessive-compulsive disorder.

Murat Yücel1, Stephen J Wood, R Mark Wellard, Ben J Harrison, Alex Fornito, Jesus Pujol, Dennis Velakoulis, Christos Pantelis.   

Abstract

OBJECTIVE: Abnormalities of the anterior cingulate cortex (ACC) have consistently been identified in obsessive-compulsive disorder (OCD), but very few studies have examined the biochemical basis of such changes. The purpose of the present study was to investigate how ACC biochemistry in OCD varies as a function of gender, hemisphere, subregion, and symptomatology.
METHOD: 3 T proton-magnetic resonance spectroscopy (MRS) was used to probe ACC biochemistry in 20 OCD patients (10 male, 10 female) and a comparable group of 26 healthy comparison subjects. Data were acquired from the left and right dorsal and rostral subregions of the ACC. Metabolites assessed included N-acetylaspartate (NAA), glutamate-glutamine (Glx), choline-containing compounds (Cho), creatine/phosphocreatine (Cr), and myoinositol-containing compounds (mI).
RESULTS: Female OCD patients had significantly reduced levels of Glx in all but one subregion of the ACC when compared to matched controls. Levels of Glx were correlated with clinical measures of symptom severity in female but not male patients. State levels of anxiety and depression did not explain this association. In addition, both male and female OCD patients had relatively higher concentrations of mI in their right ACC (rostral and dorsal) compared with healthy controls. No other compounds had any statistically significant group differences, nor were the concentrations of any other compounds correlated with symptom measures.
CONCLUSIONS: To the authors' knowledge this is the first study to demonstrate gender-specific neurochemical changes in OCD. Although these findings are tentative and require replication, they raise the possibility that MRS techniques may be of use in objectively monitoring patient progress and assessing the effectiveness of various treatments.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18465373     DOI: 10.1080/00048670802050546

Source DB:  PubMed          Journal:  Aust N Z J Psychiatry        ISSN: 0004-8674            Impact factor:   5.744


  39 in total

1.  Glutamate in Pediatric Obsessive-Compulsive Disorder and Response to Cognitive-Behavioral Therapy: Randomized Clinical Trial.

Authors:  Joseph O'Neill; John Piacentini; Susanna Chang; Ronald Ly; Tsz M Lai; Casey C Armstrong; Lindsey Bergman; Michelle Rozenman; Tara Peris; Allison Vreeland; Ross Mudgway; Jennifer G Levitt; Noriko Salamon; Stefan Posse; Gerhard S Hellemann; Jeffry R Alger; James T McCracken; Erika L Nurmi
Journal:  Neuropsychopharmacology       Date:  2017-04-04       Impact factor: 7.853

2.  An Examination of Rostral Anterior Cingulate Cortex Function and Neurochemistry in Obsessive-Compulsive Disorder.

Authors:  Brian P Brennan; Olga Tkachenko; Zachary J Schwab; Richard J Juelich; Erin M Ryan; Alison J Athey; Harrison G Pope; Michael A Jenike; Justin T Baker; William D S Killgore; James I Hudson; J Eric Jensen; Scott L Rauch
Journal:  Neuropsychopharmacology       Date:  2015-02-09       Impact factor: 7.853

3.  1H-magnetic resonance spectroscopy in obsessive-compulsive disorder: effects of 12 weeks of sertraline treatment on brain metabolites.

Authors:  Raşit Tükel; Kubilay Aydın; Erhan Ertekin; Seda Şahin Özyıldırım; Mehmet Barburoğlu
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-09-26       Impact factor: 5.270

4.  MRSI correlates of cognitive-behavioral therapy in pediatric obsessive-compulsive disorder.

Authors:  Joseph O'Neill; John C Piacentini; Susanna Chang; Jennifer G Levitt; Michelle Rozenman; Lindsey Bergman; Noriko Salamon; Jeffry R Alger; James T McCracken
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2011-10-01       Impact factor: 5.067

5.  Association between the NMDA glutamate receptor GRIN2B gene and obsessive-compulsive disorder.

Authors:  Pino Alonso; Mónica Gratacós; Cinto Segalàs; Georgia Escaramís; Eva Real; Mónica Bayés; Javier Labad; Clara López-Solà; Xavier Estivill; José M Menchón
Journal:  J Psychiatry Neurosci       Date:  2012-07       Impact factor: 6.186

6.  Neurochemicals measured by (1)H-MR spectroscopy: putative vulnerability biomarkers for obsessive compulsive disorder.

Authors:  Sundar Gnanavel; Pratap Sharan; Sudhir Khandelwal; Uma Sharma; Naranamangalam R Jagannathan
Journal:  MAGMA       Date:  2013-12-12       Impact factor: 2.310

7.  In vivo effects of ketamine on glutamate-glutamine and gamma-aminobutyric acid in obsessive-compulsive disorder: Proof of concept.

Authors:  Carolyn I Rodriguez; Lawrence S Kegeles; Amanda Levinson; R Todd Ogden; Xiangling Mao; Matthew S Milak; Donna Vermes; Shan Xie; Liane Hunter; Pamela Flood; Holly Moore; Dikoma C Shungu; Helen B Simpson
Journal:  Psychiatry Res       Date:  2015-06-06       Impact factor: 3.222

Review 8.  Brain imaging in pediatric obsessive-compulsive disorder.

Authors:  Frank P MacMaster; Joseph O'Neill; David R Rosenberg
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2008-11       Impact factor: 8.829

9.  In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD).

Authors:  Mohammad Haghighi; Leila Jahangard; Hamid Mohammad-Beigi; Hafez Bajoghli; Hassan Hafezian; Alireza Rahimi; Hamid Afshar; Edith Holsboer-Trachsler; Serge Brand
Journal:  Psychopharmacology (Berl)       Date:  2013-03-23       Impact factor: 4.530

10.  Glutamate system genes and brain volume alterations in pediatric obsessive-compulsive disorder: a preliminary study.

Authors:  Ke Wu; Gregory L Hanna; Philip Easter; James L Kennedy; David R Rosenberg; Paul D Arnold
Journal:  Psychiatry Res       Date:  2012-11-13       Impact factor: 3.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.